Additional file 1: Figure S1. of MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy

Annual changes in disease activity score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and European League Against Rheumatism (EULAR) response. Figure S2. Receiver operating characteristic (ROC) curve analysis showing that serum matrix metalloproteinase-3 (MMP-3) levels measured at the outset of methotrexate (MTX) monotherapy can predict radiographic evidence of non-progression in male (a) and female (b) patients, respectively. Table S1. Relationship between disease activity score (DAS) and van der Heijde modified total Sharp score year-progression (∆TSS). (DOCX 1416 kb

Analysis of the response and toxicity to gefitinib of non-small cell lung cancer

Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR), which had antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). We analyzed the efficacy, toxicitiy, and overall survival time of gefitinib in patients with NSCLC. Patients and Methods: One hundred and twenty-two patients with NSCLC who received gefitinib between 2002 and 2004 in our institutes were evaluated retrospectively. Results: The objective response rate was 24.6%. The variables identified as significant in univariate analysis included gender and smoking habit. The median overall survival time was 14.4 months. Significant variables associated with improved survival included good performance status (PS), female, adenocarcinoma and never smoked status, and never smoked status and good PS were independent prognostic factors in multivariate analysis. Four patients (3.3%) developed interstitial pneumonitis associated with gefitinib. Conclusion: Gefitinib showed favorable anti-tumor activity in females, never smokers and adenocarcinoma